(S)-N-[[3-[3-fluoro-4-[1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]difluoroacetamide | 640772-88-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: (S)-N-[[3-[3-fluoro-4-[1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]difluoroacetamide
• 英文别名: 2,2-difluoro-N-{[(5S)-3-(3-fluoro-4-piperazin-1-ylphenyl)-2-oxo-1,3-oxazolidin-5-yl]methyl}acetamide；2,2-difluoro-N-{[3-(3-fluoro-4-piperazin-1-ylphenyl)-2-oxo-1,3-oxazolidin-5(S)-yl]methyl}acetamide；(S)-N-[[3-[3-Fluoro-4-(1-piperazinyl)-phenyl]-2-oxo-5-oxazolidinyl]methyl]-difluoroacetamide；2,2-difluoro-N-[[(5S)-3-(3-fluoro-4-piperazin-1-ylphenyl)-2-oxo-1,3-oxazolidin-5-yl]methyl]acetamide
• CAS: 640772-88-9
• 化学式: C₁₆H₁₉F₃N₄O₃
• 分子量: 372.347
• InChiKey: HSNHEJHJPDTRDT-NSHDSACASA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  26
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  73.9
• 氢给体数：
  2
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  (S)-N-[[3-[3-fluoro-4-[1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]difluoroacetamide 在 劳森试剂 、 N,N-二甲基丙烯基脲 、 盐酸 、 碳酸氢钠 作用下， 以 四氢呋喃 、 水 为溶剂， 反应 18.0h， 生成 2,2-difluoro-N-{[(5S)-3-(3-fluoro-4-piperazin-1-ylphenyl)-2-oxo-1,3-oxazolidin-5-yl]methyl}ethanethioamide
  参考文献：
  名称：

  [EN] GLYCOLOYL-SUBSTITUTED OXAZOLIDINONE-DERIVATIVES AS ANTIBACTERIAL AGENTS
  [FR] DERIVES D'OXAZOLIDINONE GLYCOLOYL-SUBSTITUEE UTILISES COMME AGENTS ANTI-BACTERIEN

  摘要：

  本发明描述了一种具有甘氨酰哌嗪取代基的二氟硫代乙酰胺噁唑啉酮I式化合物，作为新型抗菌剂，以及用于对抗由革兰氏阳性和革兰氏阴性细菌引起的感染性疾病的抗微生物联合治疗。

  公开号：

  WO2004002479A1
• 作为产物：
  描述：

  tert-butyl (S)-4-(4-(5-((2,2-difluoroacetamido)methyl)-2-oxooxazolidin-3-yl)-2-fluorophenyl)piperazine-1-carboxylate 在 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 反应 2.0h， 生成 (S)-N-[[3-[3-fluoro-4-[1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]difluoroacetamide
  参考文献：
  名称：

  Synthesis and biological activity of novel oxazolidinones

  摘要：

  A number of 5-substituted derivatives of Ranbezolid, a novel oxazolidinone were synthesized. Antibacterial activity of the compounds against a number of sensitive and resistant bacteria showed promising results. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.09.054

文献信息

• [EN] OXAZOLIDINONE DERIVATIVES AS ANTIMICROBIALS<br/>[FR] DERIVES D'OXAZOLIDINONE UTILISES COMME AGENTS ANTIMICROBIENS
  申请人：RANBAXY LAB LTD

  公开号：WO2004014392A1

  公开（公告）日：2004-02-19

  The present invention relates to certain substituted phenyl oxazolidinones and to processes for the synthesis of the same. This invention also relates to pharmaceutical compositions containing the compounds of the present invention as antimicrobials. The compounds are useful antimicrobial agents, effective against a number of human and veterinary pathogens, including gram-positive aerobic bacteria such as multiple-resistant staphylococci, streptococci and enterococci as well as anaerobic organisms such as Bacterioides spp. and Clostridia spp. species, and acid fast organisms such as Mycobacterium tuberculosis, Mycobacterium avium and Mycobacterium spp.

  本发明涉及某些取代苯基噁唑烷酮及其合成方法。本发明还涉及含有本发明化合物作为抗微生物剂的药物组合物。这些化合物是有用的抗微生物剂，对许多人类和兽医病原体具有有效作用，包括革兰氏阳性的好氧菌，如多重耐药葡萄球菌、链球菌和肠球菌，以及厌氧菌，如拟杆菌属和梭菌属菌种，以及酸性快速菌，如结核分枝杆菌、非结核分枝杆菌和分枝杆菌属菌种。
• Difluorothioacetamides of oxazolidinones with a glycoloylpiperazine substituent
  申请人：——

  公开号：US20040072842A1

  公开（公告）日：2004-04-15

  The present invention describes difluororthioacetamide oxazolidinones with a glycoloylpiperazine substituent as novel antibacterial agents, and antimicrobial combination therapies for combating infective diseases caused by gram-positive and gram-negative bacteria.

  本发明描述了具有甘氨酰哌嗪取代基的二氟硫代乙酰胺噁唑啉作为新型抗菌剂，以及用于对抗由革兰氏阳性和革兰氏阴性细菌引起的感染性疾病的抗微生物组合疗法。
• Oxazolidinone derivatives as antimicrobials
  申请人：Mehta Anita

  公开号：US20060293307A1

  公开（公告）日：2006-12-28

  The present invention relates to certain substituted phenyl oxazolidinones and to processes for the synthesis of the same. This invention also relates to pharmaceutical compositions containing the compounds of the present invention as antimicrobials. The compounds are useful antimicrobial agents, effective against a number of human and veterinary pathogens, including gram-positive aerobic bacteria such as multiple-resistant staphylococci, streptococci and enterococci as well as anaerobic organisms such as Bacterioides spp. and Clostridia spp. species, and acid fast organisms such as Mycobacterium tuberculosis, Mycobacterium avium and Mycobacterium spp.

  本发明涉及某些取代苯基噁唑烷酮以及其合成方法。本发明还涉及含有本发明化合物作为抗微生物药物的制药组合物。这些化合物是有用的抗微生物剂，对许多人类和兽医病原体具有有效作用，包括革兰氏阳性的需氧菌，如多重耐药葡萄球菌、链球菌和肠球菌，以及厌氧菌，如Bacterioides属和Clostridiaspp.种，以及酸性快速生长菌，如结核分枝杆菌、埃维菌分枝杆菌和分枝杆菌属。
• Novel and potent oxazolidinone antibacterials featuring 3-indolylglyoxamide substituents
  作者：Mohamed Takhi、Gurpreet Singh、C. Murugan、Nirvesh Thaplyyal、Soma Maitra、K.M. Bhaskarreddy、P.V.S. Amarnath、Arundhuti Mallik、T. Harisudan、Ravi Kumar Trivedi、K. Sreenivas、N. Selvakumar、Javed Iqbal

  DOI：10.1016/j.bmcl.2008.03.043

  日期：2008.9

  Novel oxazolidinone antibacterials bearing a variety of 3-indolylglyoxamide substituents have been explored in an effort to improve the spectrum and potency of this class of agents. A subclass of this series was also made with the diversity at C-5 terminus. These derivatives have been screened against a panel of clinically relevant Gram-positive pathogens and fastidious Gram-negative organisms. Several analogs in this series were identified with in vitro activity superior to linezolid ( MIC = 0.25-2 mu g/ mL). Compounds 10a, 10c, 10e and 10f displayed activity against linezolid resistant Gram-positive organisms (MIC = 2-4 mu g/ mL). Selected oxazolidinones were evaluated for in vivo efficacy against a mouse systemic infection model. (C) 2008 Elsevier Ltd. All rights reserved.
• WO2008/10070
  申请人：——

  公开号：——

  公开（公告）日：——